Especially, because iNKT cells exhibit direct cytotoxicity against CD1d-expressing glioblastoma cells, we propose that the adoptive immunotherapy of iNKT cells should be an ideal therapeutic strategy for glioblastoma. This evidence concerns the gene CD1D and glioblastoma.